Ind-Swift Laboratories Limited issued a corrigendum to its Extraordinary General Meeting (EGM) notice on July 29, 2026, in response to specific queries raised by the National Stock Exchange of India Limited and BSE Limited regarding its proposed capital raise. The company’s Preferential Issue Committee approved the necessary modifications to the Explanatory Statement included in the original EGM notice dated July 29, 2026, ensuring compliance with regulatory requirements before shareholders vote on the matter.

The regulatory scrutiny followed query letters received from the National Stock Exchange of India Limited on July 20, 2026, and from BSE Limited on July 22, 2026. These exchanges requested certain clarifications or changes to Item No. 1 of the EGM Notice, which seeks shareholder approval for a Preferential Issue of Fully Convertible Warrants. The company stated that all other terms, conditions, and contents of the original EGM Notice remain unchanged and valid, with only the specified modifications incorporated into the corrigendum.

EGM Schedule and Details

The Extraordinary General Meeting is scheduled to take place on Wednesday, August 05, 2026, at 11:30 A.M. (IST). In adherence to current norms, the meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). Shareholders are required to review the updated Explanatory Statement contained within the corrigendum before casting their votes on the warrant issuance.

The Preferential Issue Committee convened on July 29, 2026, commencing at 04:45 P.M. and concluding at 05:15 P.M., to finalize the corrigendum. Pardeep Verma, VP - Corporate Affairs & Company Secretary, authorized the circulation of the corrected notice to members and its submission to the stock exchanges.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates timely disclosure of material events, including board resolutions and significant corporate actions such as preferential issues. By issuing the corrigendum, Ind-Swift Laboratories Limited aims to ensure that shareholders have accurate and complete information regarding the Fully Convertible Warrants issue before the vote.

The company’s registered office is located at SCO 850, Shivalik Enclave, NAC Manimajra, Sector 13, Chandigarh. It operates manufacturing facilities in Punjab and Jammu & Kashmir. The corporate action reflects standard procedural adjustments often seen when exchanges seek additional clarity on complex financial instruments like warrants prior to shareholder approval.

Ind-Swift Laboratories has executed a memorandum of understanding with Him Infratech Private Limited for the construction of a centralized warehouse facility, marking a significant step in its infrastructure expansion plans. The agreement, signed on July 28, 2026, carries an estimated contract cost of ₹40 crore and is designed to enhance the company's storage capabilities and logistical efficiency. The new facility will be located on leasehold land spanning approximately 4.5 acres in Village Jawaharpur, Derabassi, Punjab, adjoining the company's existing manufacturing unit in the Global Business Unit.

The warehouse is projected to have a storage capacity of 11,000 pallets, dedicated to holding raw materials, packing materials, and finished goods. Ind-Swift Laboratories disclosed the transaction under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also referenced SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company confirmed that Him Infratech holds no shareholding in Ind-Swift Laboratories, and the transaction does not classify as a related-party transaction under the Listing Obligations and Disclosure Requirements.

Project Details

The construction timeline for the warehouse facility is set at 300 days, excluding any exigencies. The strategic location adjacent to the existing manufacturing facility in Derabassi allows for seamless integration with current operations. By centralizing storage for raw and finished goods, the company aims to reduce logistical bottlenecks and improve supply chain responsiveness. The absence of any shareholding or promoter-group relationship between the two entities ensures the transaction is conducted at arm's length.

Strategic Implications

This infrastructure investment underscores Ind-Swift Laboratories' focus on scaling its operational backbone to support future growth. The addition of a high-capacity centralized warehouse addresses potential constraints in storage and distribution, which are critical for maintaining product availability and reducing lead times. With the facility situated near its primary manufacturing hub in Punjab, the company can optimize inventory management and streamline the movement of goods from production to market. The execution of this MOU signals a commitment to long-term operational resilience and efficiency improvements within its supply chain framework.